Clinical trials: Acarbose
Type 2 Diabetes Mellitus
A Phase IV Study in Drug-Naive Patients With T2DM in China
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared with Acarbose in patients with T2DM who were…
- Trial name
- NCT03344341
- Testing
- Dapagliflozin, Acarbose
- Where
- 20 sites in China
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
The purpose of the study is to determine if the administration of small doses of Acarbose can prevent or delay the appearance of Type 2 Diabetes Mellitus in a population of subjects with prediabetes.
- Trial name
- NCT01010100
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- 23 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Bayer
Tolerance, Side Effect
The Efficacy and Tolerability of Acarbose in Healthy Individuals
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
- Conditions
- Tolerance, Side Effect, Glucose Response
- Trial name
- NCT05542849
- Testing
- Acarbose Tablets 50mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Overweight or Obesity
Study Exploring the Supportive Effect of Acarbose in Weight Management
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination…
- Trial name
- NCT05934110
- Testing
- EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,
- Where
- 3 sites in Sweden
- Volunteers
- 320 people
- Sponsor
- Empros Pharma AB
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes
This study is not being conducted in the United States. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to acarbose in lowering overall blood glucose levels in…
- Trial name
- NCT00110240
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 594 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic metabolic disorder which is caused by both insulin secretion deficiency and insulin action defect.
- Conditions
- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in, Subjects With Type 2 Diabetes Mellitus.
- Trial name
- NCT01245166
- Testing
- Acarbose, Metformin/Acarbose
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- Lotus Pharmaceutical
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition…
- Trial name
- NCT01709305
- Testing
- Metformin, Sitagliptin, Acarbose
- Volunteers
- 5,570 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events.
- Trial name
- ABDOMEN (NCT01167231)
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- Poland
- Volunteers
- 3,310 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
The study is designed as non interventional to collect data on the safety especially, severe hypoglycemia or documented symptomatic hypoglycemic episodes and effectiveness of acarbose/metformin fixed-dose combination under…
- Trial name
- GLORY (NCT01915264)
- Testing
- Acarbose/Metformin (Glucobay M, BAY81-9783)
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
To demonstrate the efficacy and safety of acarbose and metformin loose-dose combination as compared to metformin monotherapy in the treatment of subjects with T2DM that is inadequately controlled by metformin alone
- Trial name
- NCT03349684
- Testing
- Acarbose, Metformin
- Where
- 29 sites in China
- Volunteers
- 287 people
- Sponsor
- Bayer
Type 2 Diabetes
GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients
An observational and multicenter study to assess the effectiveness and safety of Glucobay®- M under daily life treatment of type-2 diabetes patients.The study objectives are to investigate the effectiveness and safety of…
- Trial name
- GLOBE (NCT01219582)
- Testing
- Glucobay M (Acarbose/Metformin, BAY81-9783)
- Where
- India
- Volunteers
- 9,364 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) taken without or with water and the Glucobay standard tablet taken with water
- Trial name
- NCT01388153
- Testing
- Acarbose (Glucobay ODT, BAYG5421), Acarbose (Glucobay, BAYG5421)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.
- Trial name
- NCT02049814
- Testing
- Metformin, Voglibose, Acarbose
- Where
- 18 sites in China
- Volunteers
- 494 people
- Sponsor
- Takeda
Diabetes Mellitus
Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy
The study is designed as non interventional to collect data on the effectiveness of acarbose and metformin monotherapy, respectively, in terms of change from baseline in post prandial blood glucose level at the end of 16 weeks in…
- Trial name
- STARCH AM (NCT01961388)
- Testing
- Bay G5421 Glucobay, Metformin
- Sponsor
- Bayer
Diabetes Mellitus
Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting
It has been recently suggested, that not the diet by itself, but also patient's adherence to dietary recommendations and all actions performed to improve dietary compliance, may be a significant factor influencing blood glucose…
- Trial name
- CATERING (NCT01333774)
- Testing
- Glucobay (Acarbose, BAYG5421)
- Where
- Poland
- Volunteers
- 423 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2 Diabetic Patients Using Two Different Formulations of Acarbose 50mg.
- Trial name
- NCT01316861
- Testing
- EMS Acarbose, Bayer Acarbose
- Where
- Brazil
- Volunteers
- 79 people
- Sponsor
- EMS
Type 2 Diabetes Mellitus
Diabetes Treatment With Glucobay in Combination With Sulfonylurea
In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of sulfonylurea under daily life treatment…
- Trial name
- NCT01613105
- Testing
- Acarbose (Precose/Glucobay, BAYG5421)
- Where
- India
- Volunteers
- 4,564 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus…
- Trial name
- NCT01030952
- Testing
- Nateglinide, Acarbose
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals